← Pluristem Therapeutics Inc. (PLX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Pluristem Therapeutics Inc. (PLX)
Biological Products, (No Diagnostic Substances) · market cap $225M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Pluristem Therapeutics (PLX) is an Israeli biotech with a market cap of ~$197M developing PLX-PAD, a placental-derived cell therapy, across three clinical programs including a Phase 3 trial in hip fracture. Notably, the company description provided references Protalix BioTherapeutics and its plant-based enzyme taliglucerase alfa for Gaucher disease — a material discrepancy in the sourced facts that introduces uncertainty about the exact revenue base underpinning reported financials. The next scheduled catalyst is an earnings release on 2026-08-13.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PLX-PAD | Phase 3 | Hip Fracture |
| PLX-PAD Low dose | Phase 2 | Intermittent Claudication |
| 150M PLX-PAD | Phase 2 | Total Hip Arthroplasty |
Price & technical context
3-month
+15.5%
6-month
+22.4%
12-month
+20.7%
52-wk range
$1.67–$3.15
vs 50-day MA
+5.8%
vs 200-day MA
+15.0%
Realized vol
63.6%
Max drawdown
-56.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PLX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.